Dr Christine Roder

Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients

C Roder, C Cosgrave, K Mackie, S Roberts, M Hellard, A Wade, J Doyle

(2023), Vol. 15, pp. 1-10, Viruses, Basel, Switzerland, C1

Area-level social and economic factors and the local incidence of SARS-CoV-2 infections in Victoria during 2020

C Roder, C Maggs, B McNamara, D O'Brien, A Wade, C Bennett, J Pasco, E Athan

(2022), Vol. 216, pp. 349-356, Medical Journal of Australia, London, Eng., C1

High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study

J Yee, J Carson, B Hajarizadeh, J Hanson, J O’Beirne, D Iser, P Read, A Balcomb, J Doyle, J Davies, M Martinello, P Marks, G Dore, G Matthews, G Matthews, C Roder

(2022), Vol. 6, pp. 496-512, Hepatology Communications, Chichester, Eng., C1

Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort

J Carson, B Hajarizadeh, J Hanson, J O'Beirne, D Iser, P Read, A Balcomb, J Davies, J Doyle, J Yee, M Martinello, P Marks, G Matthews, G Dore, J Post, R Batey, J Smart, O Dawson, S Hill, M Douglas, M Montebello, P Collie, R Hallinan, G Snelgar, D Baker, S Galhenage, T Soo, R Bopage, J Faros, L Cooper, R Nelson, D Shaw, M Wilson, W Pratt, S Hinton, A Wade, H Van Gessel, L Davidson, M Dibdin, M Lucas, R Ahmad, D Smith, K Tan, C Roder, B Harney, S Holdaway, J Walsh, P Fox, R Mousavi, W Lam, R Dahal, P Habel, R Gilliver, E Silins, J Ackerman, R Deacon, E Hall, A Everson, J Stewart, M Milner, C Ferguson, J Tate-Baker, J Bradshaw, G Duncan, G Baluran, B Watson, C Hey, R Hickey, C Orme, S Miczkova

(2022), Vol. 29, pp. 661-676, Journal of Viral Hepatitis, England, C1-1

Successful expanded clinic network collaboration and patient tracing for retention in HIV care

S Bhatt, M Bryant, H Lau, B Tee, B Eu, J O’Bryan, I Woolley, J Mitchell, A Street, S Dobinson, N Medland, J Lamb, A Mahony, A Tramontana, L Lim, A Wade, C Roder, W Mitchell, C Sherman, F Bramwell, C Aboltins, S Wong, M Giourouki, J Hoy, J McMahon

(2022), Vol. 19, pp. 61-, AIDS Research and Therapy, England, C1-1

Cost and Outcomes of Implantable Cardiac Electronic Device Infections in Victoria, Australia

C Roder, V Gunjaca, O Otome, S Gwini, E Athan

(2020), Vol. 29, pp. E140-E146, Heart Lung and Circulation, Amsterdam, The Netherlands, C1

In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection

C Roder, E Athan

(2020), Vol. 20, pp. 209-216, Drugs in R and D, New Zealand, C1

Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings

R Gupta, C Calderwood, A Yavlinsky, M Krutikov, M Quartagno, M Aichelburg, N Altet, R Diel, C Dobler, J Dominguez, J Doyle, C Erkens, S Geis, P Haldar, A Hauri, T Hermansen, J Johnston, C Lange, B Lange, F van Leth, L Muñoz, C Roder, K Romanowski, D Roth, M Sester, R Sloot, G Sotgiu, G Woltmann, T Yoshiyama, J Zellweger, D Zenner, R Aldridge, A Copas, M Rangaka, M Lipman, M Noursadeghi, I Abubakar

(2020), Vol. 26, pp. 1941-1949, Nature Medicine, London, Eng., C1

Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C

A Wade, A McCormack, C Roder, K McDonald, M Davies, N Scott, M Wardrop, E Athan, M Hellard

(2018), Vol. 25, pp. 1089-1098, Journal of Viral Hepatitis, England, C1

Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand

J Trubiano, A Cheng, T Korman, C Roder, A Campbell, M May, C Blyth, J Ferguson, T Blackmore, T Riley, E Athan

(2016), Vol. 46, pp. 479-493, Internal Medicine Journal, Australia, C1

Auranofin: repurposing an old drug for a golden new age

C Roder, M Thomson

(2015), Vol. 15, pp. 13-20, Drugs in R&D, Auckland, N.Z, C1